 The launch of anti-VEGFs did not only revolutionize the management of the wet-age-related macular degeneration (AMD) and diabetic macular edema (DME) markets but also increased its economic burden
INTRODUCTION
 Manufacturers need to continue optimizing their product offerings after launch, to defend their price and market share as competition increases and/ or expand in new markets with higher return on investment potential
• Engaging with Payers to understand their needs and expectations and investing in evidence generation strategies to support the product value are imperative for success across lifecycle  Offering direct discounts, managed entry agreements and value adding services is also key, employing different approaches depending on Payer types per market
• In France, Payers prefer price-volume agreements, resulting to list price drops every time that the patient volume increases (through additional indications)
• In the UK and Germany (prior to AMNOG), list prices are not affected by new indications -In the UK, NICE negotiates confidential PAS with manufacturers of high cost drugs to reach cost effectiveness thresholds before issuing a positive recommendation for use at the local level -In Germany, there are fixed discounts compulsory for all drugs and, less frequently, performancebased risk sharing schemes, negotiated at the SHI level -Since AMNOG, Germany is no longer a free pricing market and price depends on benefit assessment  Secondary research was conducted to identify official list prices for Lucentis (ranibizumab), Eylea (aflibercept), Macugen (pegaptanib), Ozurdex (dexamethasone), Visudyne (verteporfin) in the three largest European markets from launch to September 2015 using the following sources:
• The British National • Based on licensed dosing and list prices, Lucentis is the most expensive anti-VEGF; however, public sources indicate that the estimated confidential discount offered for Lucentis across the 5EU markets was around 45% (in 2014) 6  Since launch, Lucentis faces competition from cheaper Avastin which is used off-label in the UK and Germany • Price per injection is similar but required injections per year are fewer than those required for Lucentis, resulting in lower annual treatment cost (7 versus 12 injections/ year respectively) 7 • Annual cost of treatment with Eylea is 36 to 42% cheaper compared to Lucentis in the studied countries • In the UK, price has remained stable, likely due to the negotiated risk-sharing and confidential discount agreements. In 2008, uncertainty around the Lucentis 'stopping rule' led to a negotiated risk sharing scheme providing free injections to patients after receiving 14 doses. 10 The scheme was replaced in 2012 by a confidential discount Patient Access Scheme (PAS) on list price
• In France, the price of Lucentis drops over time as new indications come  Due to different market characteristics, the impact of indication expansion on price varies across the markets in scope  Maintaining a high list price is complicated in price regulated countries  List prices are not affected by subsequent indications in free pricing markets, where contracting and confidential discounts are usually key for access  To maintain high list prices and avoid impact of international price referencing, PAS may be potential options, but acceptability and type may vary across countries  In high economic burden markets, off-label use of cheaper alternatives may force manufacturers of on-label agents to significantly drop their prices in order to remain competitive, especially when off-label use is endorsed by Payers
